[上海]柯惠医疗研发部招聘实习生

发布时间：2016-03-16
工作地点：上海
信息来源：上海理工大学bbs
职位类型：兼职
职位描述
招聘职位：柯惠医疗研发部实习生
工作地点：上海市闵行区漕河泾高科园区（8号线浦江镇地铁站）

应聘要求

 专业： 机械/ 控制/ 自动化等，有硬件在环仿真（simulink + NI labview）相关项目经历
 学历：硕士研究生在读或大四本科
 每周实习时间：保证每周工作3天以上，持续三个月，能够长期实习的优先考虑
 熟练的英语听说读写，可以在英语环境下工作
 自我激励，热情，结果导向，能够同时处理多项工作
 注重技术细节，具有较强的学习和动手能力，善于解决问题

待遇
午餐+实习补助

联系方式
刘 021-33230023 shanshan.liu@
发送邮件内容包括：

简历（详细描述硬件在环仿真simulink + NI Labview相关项目+所学课程）

可到职时间

每周工作时间

公司简介
Covidien, 自2007年从泰科集团公司分离而独立上市，成为世界医疗器械行业十强企业，年营业收入达１００亿美元，全球４３，０００名员工生产５０，０００种医疗产品。 Covidien（柯惠）的使命是维护与医疗专业人士合乎道德的合作，创造并提供创新的医疗解决方案，从而提高患者的生活质量，同时增加客户以及股东的收益。
Covidien, separated from Tyco International Ltd and already become an independent, publicly-traded company and one of the world's largest global healthcare companies. With $10 billion revenue, Covidien has more than 43,000 employees worldwide and more than 50,000 products. The mission of Covidien is to Create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals, which enhance the quality of life for patients and improve outcomes for our customers and our shareholders.

Covidien has identified Emerging Markets worldwide - with a particular emphasis on Asia and a focus on China and India - as offering significant potential for organizational growth and business success. Included within the many facets of the Company's growth strategy is development of a global Medical Devices Emerging Markets R&D group whose vision is:

As Covidien works toward its goal of becoming the leading global healthcare products company, we will support this goal by developing innovative products that balance cost and features, tailoring these products to the different geographic markets we serve and increasing speed to market in making these products available to our customers.

Covidien's commitment to growing its global R&D function is significant. The organization's R&D funding in 2007 stood at $260 million. That increased to $447 million - up 72 percent - in 2010 and the total will reach more than half a billion dollars by 2013.

In its effort to reach the desired outcomes, Emerging Markets R&D is:

Growing R&D funding to an appropriate level

Continuing to be GBU-focused in most areas

Pooling resources where efficiencies can be gained, like governance and support

Finding opportunities to combine technologies across GBUs to develop breakthrough processes

The EM R&D strategy includes four of Covidien's Global Business Units - Surgical Devices, Vascular Therapies, Energy-based Devices and Respiratory & Monitoring Solutions. Those businesses account for more than 65 percent of Covidien's revenues.